Pfizer's plan to market its complementary statin drug only in combination with its Lipitor, denying alternatives for patients who might need them, is "a terrible precedent" for the drug industry, The New York Times editorial says. Torcetrapib is still in trial, but by tying it to Lipitor, the company will be able to extend the Lipitor patent and, in combination, create a blockbuster bigger than Lipitor.

Full Story:

Related Summaries